| Document |
Document Title |
|
WO/2023/231795A1 |
The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a heterocyclic compound and the use thereof. The structural formula of the compound is as shown in formula (I). The...
|
|
WO/2023/235809A1 |
The present invention relates to novel cGAS inhibitor compounds, to pharmaceutical compositions comprising the compounds, and to methods of using the compounds and compositions to treat certain pathological conditions.
|
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/232133A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or an eutectic thereof, and an intermediate and a...
|
|
WO/2023/232113A1 |
Disclosed are a piperazinone compound, a preparation method therefor and a use thereof. Specifically, disclosed are a compound represented by formula I, and a tautomer, stereoisomer or pharmaceutically acceptable salt thereof. The compou...
|
|
WO/2023/230968A1 |
Provided are an SHP2 inhibitor, and a crystal form thereof, a preparation method therefor, and a use thereof. Provided are a crystal form B of a compound as shown in formula (I), a compound as shown in formula (II) and a crystal form A t...
|
|
WO/2023/235618A1 |
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical composit...
|
|
WO/2023/233130A1 |
The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...
|
|
WO/2023/229265A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device comprising the organic electric element. According to the present invention, an organic electri...
|
|
WO/2023/230249A1 |
Described herein are methods of treating and preventing disease due to infection with Hepatitis A Virus in a subject in need thereof, comprising administering any one of the hepatoselective inhibitors of PAPD 5 and 7, described herein.
|
|
WO/2023/230288A1 |
Disclosed herein is a method of treating breast cancer by administering 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-
oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile, alone or in combination with a second agent such ...
|
|
WO/2023/230262A1 |
The present application provides tricyclic compounds that modulate the activity of the PI3Kα, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2023/227125A1 |
Disclosed in the present invention is a new fused-heterocyclic compound having target inhibitory activity for CDKs, and specifically disclosed is a compound having a structure as represented by formula (I) as a target inhibitor for CDKs ...
|
|
WO/2023/229346A1 |
The present invention relates to: a novel compound for inhibiting nicotinamide phosphoribosyltransferase (NamPT); a composition including same; and various uses thereof.
|
|
WO/2023/227734A1 |
The invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treat...
|
|
WO/2022/221227A9 |
Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing canc...
|
|
WO/2023/227139A1 |
The invention relates to a novel fused pyrimidine compound as shown in general formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and preparation methods and uses therefor. The meanings of R1, R2,...
|
|
WO/2023/227080A1 |
Provided are a PROTAC compound, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. The PROTAC compound has a structure as represented by formula (I), and can be used for treating BTK-rela...
|
|
WO/2023/227117A1 |
Provided in the present invention is a 3C-like protease inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof. Also provided in ...
|
|
WO/2023/227867A1 |
The present invention provides compounds of formula (I): 5 A 1 X Y N R 2 R 1 A 2 A 3 A 4 n Formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1, R2, n, A1, A2, A3, A4, X and Y are as defined in the...
|
|
WO/2023/230217A1 |
Provided herein are antileishmanial compounds, compositions comprising the antileishmanial compounds, and use thereof.
|
|
WO/2023/227703A1 |
The present specification relates to novel physical forms of a indazole-5-carboxamide derivative, as well as solvate and salt forms of the same compound. A process for the preparation of the compound and uses of the new physical forms ar...
|
|
WO/2023/228974A1 |
Provided are: a material with which the high sensitivity and high resolution of a photoelectric conversion element for imaging are achieved; and a photoelectric conversion element for imaging using the same. This material for a photoel...
|
|
WO/2023/230059A1 |
The disclosure includes compounds of Formula (1) wherein each of R, R1, R2, R2A, R3, R4, R5, R6, R, L1, L2, L3, L4, L5, L6, Q1, Q2, Q3, m, n, r, s, and t, are defined herein. Also disclosed is a method for treating a neoplastic disease, ...
|
|
WO/2023/226580A1 |
The present invention relates to a compound containing a pyrrolopyrimidine structure or a pharmaceutically acceptable salt of the compound, a preparation method therefor, a pharmaceutical composition containing the compound, and a medica...
|
|
WO/2023/227946A1 |
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
|
|
WO/2023/230190A1 |
Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.
|
|
WO/2023/221721A1 |
An SHP2 inhibitor, comprising a compound of formula (I), or a pharmaceutically acceptable salt, isomer, solvate, chelate, polymorph, acid, ester, metabolite or prodrug thereof. The present invention further relates to a pharmaceutical co...
|
|
WO/2023/222115A1 |
Provided in the present application is a hydroxyamide derivative represented by formula (I), and a tautomer, stereoisomer, solvate, metabolite, isotopically-labeled compound, pharmaceutically acceptable salt or co-crystal thereof. The co...
|
|
WO/2023/225041A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
|
|
WO/2023/223057A1 |
The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in...
|
|
WO/2023/220836A1 |
The present disclosure relates generally to new bifunctional linchpins that react selectively with cysteine residues to invoke cyclization while concurrently introducing a radiometal chelation ligand or silicon-based fluoride acceptor (S...
|
|
WO/2023/222762A1 |
The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-methyltransferase and methods of using the same.
|
|
WO/2023/225097A1 |
Provided are, inter alia, compounds having a structure of Formula (I)-(VL), pharmaceutical compositions including the same, and methods of use. In one aspect, compounds are provided that can inhibit salt-inducible kinases (SIK) and metho...
|
|
WO/2023/221048A1 |
The present disclosure provides a light-emitting material and a light-emitting device. The light-emitting material comprises a host material and a doping material, wherein the host material comprises an N-type material and a P-type mater...
|
|
WO/2023/222055A1 |
Disclosed are a series of deuterated nucleoside compounds and a use thereof. Specifically disclosed are compounds represented by formula (IV), and stereoisomers or pharmaceutically acceptable salts thereof.
|
|
WO/2023/220967A1 |
Provided are methods for producing 3,6-disubstituted-imidazo[l,2-b]pyridazine compounds or the salts thereof.
|
|
WO/2023/225664A1 |
The disclosure herein provides lactam substituted imidazopyridazine compounds of Formula (I), (II), (II-a), (II-a), (III)¸ (IV)¸ (IV-a)¸ and (IV-b), or pharmaceutical compositions thereof, for the modulation of IL-17A. These compounds...
|
|
WO/2023/221900A1 |
A selective HER2 inhibitor compound as shown in formula I or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/223335A1 |
The invention relates to a process for preparation of compound of formula (I) by reacting 2-chloro-1-(3,4-difluorophenyl)ethanone of formula (II) in a buffer and in the presence of an enzyme CDX-023 and co-enzyme NADP.
|
|
WO/2023/192933A9 |
A self-assembled nanomaterial includes a Janus base nanotube, wherein the Janus base nanotube includes at least one compound represented by Formulas I to XII, or a pharmaceutically acceptable salt thereof. Also described are compositions...
|
|
WO/2023/222644A1 |
The present invention provides novel compounds having the general formula (I) wherein ring A, ring B, ring C, bond a, and R1 to R7 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compoun...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/225244A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
|
|
WO/2023/222005A1 |
The present invention belongs to the technical field of medicines, and relates to a class of aromatic heterocyclic compounds serving as an LRRK2 inhibitor. The present invention provides a class of compounds with a novel structure, which...
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/223253A1 |
The present invention provides a process for the preparation of ruxolitinib or a pharmaceutically acceptable salt thereof. In particular, the present invention provides a process for the preparation of crystalline (R)-ruxolitinib phospha...
|
|
WO/2023/217230A1 |
The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
|
|
WO/2023/220129A1 |
The present disclosure features compounds of Formula I, Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
|
|
WO/2023/216871A1 |
A compound having a structure of formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt thereof, and an application of the compound or salt thereof in inhibiting an EGFR comprising a mutant EGFR, comprising treating canc...
|
